Group items tagged

Patients suffering from chronic and episodic migraine attacks are set to benefit from a groundbreaking recommendation by the National Institute for Health and Care Excellence (NICE) regarding a new medication. The atogepant, a first-of-its-kind preventive drug for migraine, offers hope for those grappling with this debilitating condition and can be taken orally. Published as part of the final guidance draft, NICE has greenlit the atogepant, also known as Aquipta and manufactured by AbbVie, as an option for preventing both chronic and episodic migraines in adults. Specifically, this recommendation is for individuals who have experienced at least four migraine days per month and have failed to find relief with at least three previous preventive treatments. With approximately 4.5 million people in the UK affected by various forms of migraine, this new recommendation marks a significant advancement in migraine management as the condition significantly impacts patients' day-to-day activities as well as places a heavy burden on the NHS and the wider economy.

Pharmanovia, the lifecycle management company has signed a licence and supply agreement with Aquestive Therapeutics for its patented diazepam buccal film formulation across the EU, UK, Switzerland, and Norway, as well as countries in the Middle East and North Africa (MENA)- up to 48 markets in total. Aquestive Therapeutics has been granted tentative approval by the US Food and Drug Administration (FDA), for its diazepam buccal film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. Pharmanovia will be responsible for seeking appropriate regulatory approval across EU and MENA. Pharmanovia CEO, James Burt commented: "Pharmanovia and Aquestive are aligned in our mission to find new and innovative ways to enhance and revitalise iconic medicines. We have extensive experience with diazepam through the Valium brand and, together with Aquestive's unique PharmFilm technology, we're intending to bring a novel alternative diazepam delivery option to caregivers and patients at a time of critical need."

The National Health Services England (NHSE) is poised to revolutionise diabetes management with the introduction of the 'artificial pancreas', also known as the Hybrid Closed Loop system, to treat type 1 diabetes. This pioneering initiative, endorsed by the National Institute of Health Care and Excellence (NICE), represents a global first in healthcare innovation. With 269,095 individuals grappling with type 1 diabetes in England, the Hybrid Closed Loop system is set to cater to tens of thousands of children and adults across the nation. This cutting-edge device operates by seamlessly monitoring blood glucose levels and autonomously adjusting insulin dosage through a pump, by eliminating the need for regular insulin injections. Furthermore, it holds the promise of averting life-threatening hypoglycaemic and hyperglycaemia episodes, mitigating significant risks associated with the condition. To facilitate the identification of beneficiaries, NHSE has allocated a substantial sum of £2.5 million, ensuring that those who could benefit from this innovative solution receive the necessary support.

Upload Press Release for free of ✔ Electronics ✔ Business ✔ Medical ✔ Energy ✔ Technology industry. Submit PR Free on weSRCH.com